Gary Zammit

Gary Zammit publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Gary Zammit sits on this spectrum.

Gary Zammit D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Gary Zammit sits on this spectrum.

Best Publications

• Short Sleep Duration as a Risk Factor for Hypertension Analyses of the First National Health and Nutrition Examination Survey

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  1667
  Citations

• Sleep Duration as a Risk Factor for Diabetes Incidence in a Large US Sample

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs

  739
  Citations

• Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes

  Gary D. Foster;Mark H. Sanders;Richard Millman;Gary Zammit

  738
  Citations

• Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

  A Blackman;G D Foster;G Zammit;R Rosenberg

  543
  Citations

• An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia

  Milton Erman;David Seiden;Gary Zammit;Stephen Sainati

  387
  Citations

• Earlier Parental Set Bedtimes as a Protective Factor Against Depression and Suicidal Ideation

  James E. Gangwisch;Lindsay A. Babiss;Dolores Malaspina;J. Blake Turner

  358
  Citations

• Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in Obese Patients with Type 2 Diabetes

  Samuel T Kuna;Samuel T Kuna;David M Reboussin;Kelley E Borradaile;Mark H Sanders

  272
  Citations

• Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health.

  James E. Gangwisch;Dolores Malaspina;Lindsay A. Babiss;Mark G. Opler

  268
  Citations

• Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample.

  James E. Gangwisch;Steven B. Heymsfield;Bernadette Boden-Albala;Ruud M. Buijs;Ruud M. Buijs

  266
  Citations

• Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

  Unknown

  264
  Citations

• Long-Term Efficacy and Safety of Zolpidem Extended-Release 12.5 mg, Administered 3 to 7 Nights Per Week for 24 Weeks, in Patients With Chronic Primary Insomnia: A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

  Andrew D. Krystal;Milton Erman;Gary K. Zammit;C. Soubrane

  258
  Citations

• Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

  Gary Zammit;Milton Erman;Sherry Wang-Weigand;Stephen Sainati

  251
  Citations

• A new questionnaire to detect sleep disorders.

  Thomas Roth;Gary Zammit;Clete Kushida;Karl Doghramji

  250
  Citations

• Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

  Sheldon Preskorn;Matthew Macaluso;Do Vishaal Mehra;Gary Zammit

  230
  Citations

• Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial

  Russell Rosenberg;Patricia Murphy;Gary Zammit;David Mayleben

  228
  Citations

• Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.

  Gary K. Zammit;Louis J. McNabb;Judy Caron;David A. Amato

  184
  Citations

• Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

  Paula K Schweitzer;Russell Rosenberg;Gary K Zammit;Mark Gotfried

  173
  Citations

• Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

  Patricia Murphy;Margaret Moline;David Mayleben;Russell Rosenberg

  169
  Citations

• Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes.

  Eric J. Kezirian;George S. Goding;Atul Malhotra;Fergal J. O'Donoghue

  166
  Citations

• Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.

  Mikko Kärppä;Jane Yardley;Kate Pinner;Gleb Filippov

  137
  Citations